These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 171796)

  • 1. Proceedings: Enhancement of ADP-induced platelet aggregation by isometric hand-grip excercise in sclerotic patients and its prevention by EG-626, cAMPPDE inhibitor.
    Sano T; Motimiya T; Yamazaki H; Shinamoto T
    Thromb Diath Haemorrh; 1975 Sep; 34(1):344. PubMed ID: 171796
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement of platelet sensitivity to ADP-aggregation by isometric exercise in arteriosclerosis patients and its prevention.
    Sano T; Motomiya T; Yamazaki H; Shimamoto T
    Thromb Haemost; 1977 Apr; 37(2):329-38. PubMed ID: 195363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effects of UK 14,275: evaluation of a new phosphodiesterase inhibitor with inotropic properties in animals and human volunteers [proceedings].
    Follath F; Kersting F; Lewis GR; Dollery CT
    Br J Clin Pharmacol; 1975 Aug; 2(4):372P-373P. PubMed ID: 184804
    [No Abstract]   [Full Text] [Related]  

  • 4. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
    Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
    Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
    Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
    J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
    [No Abstract]   [Full Text] [Related]  

  • 6. [The mode of action and clinical applications of phosphodiesterase inhibitors as anti-platelet drugs].
    Murohara Y; Takatsu Y; Yui Y; Kawai C
    Nihon Rinsho; 1989 Apr; 47(4):935-9. PubMed ID: 2545947
    [No Abstract]   [Full Text] [Related]  

  • 7. [Inhibition of platelet aggregation and cyclic nucleotide phosphodiesterase (specifically cyclAMP) by 3-hydroxypyridine derivatives].
    Kagan VE; Polianskiĭ NB; Muranov KO; Shvedova AA; Smirnov LD
    Biull Eksp Biol Med; 1984 Apr; 97(4):416-8. PubMed ID: 6202339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet aggregation and cyclic nucleotide phosphodiesterase activity in arteriosclerotic patients.
    Yamazaki H; Motomiya T; Mashimo N; Asano T; Hidaka H
    Thromb Haemost; 1978 Feb; 39(1):158-66. PubMed ID: 205971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
    Nemoz G; Prigent AF
    Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
    [No Abstract]   [Full Text] [Related]  

  • 10. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
    Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
    Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors.
    Ashida S; Sakuma K
    Adv Second Messenger Phosphoprotein Res; 1992; 25():229-39. PubMed ID: 1313259
    [No Abstract]   [Full Text] [Related]  

  • 12. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect.
    Jackson C; Ball J; Peel J; Lawry J; Greaves M; Preston FE
    Thromb Haemost; 1989 Apr; 61(2):266-9. PubMed ID: 2546286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
    Lam SC; Guccione MA; Packham MA; Mustard JF
    Thromb Haemost; 1982 Apr; 47(2):90-5. PubMed ID: 6285543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
    Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
    J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
    Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
    Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour.
    Sills T; Heptinstall S
    Thromb Haemost; 1986 Jun; 55(3):305-8. PubMed ID: 3018954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity.
    Abbott BM; Thompson PE
    Bioorg Med Chem Lett; 2006 Feb; 16(4):969-73. PubMed ID: 16290931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of four methylxanthine compounds and norepinephrine on cardiac phosphorylase activation and cardiac contractility.
    McNeill JH; Brenner MJ; Muschek LD
    Recent Adv Stud Cardiac Struct Metab; 1973; 3():261-73. PubMed ID: 4377599
    [No Abstract]   [Full Text] [Related]  

  • 20. Drugs and foods on contraction of endothelial cells as a key mechanism in atherogenesis and treatment of atherosclerosis with endothelial-cell relaxants (cyclic AMP phosphodiesterase inhibitors).
    Shimamoto T
    Adv Exp Med Biol; 1975; 60():77-105. PubMed ID: 167561
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.